In better news: They're totally treatable and actually pretty common (especially for makeup wearers).

Irvine-based Tarsus Pharmaceuticals posted blockbuster Q4 and full year revenues driven by surging demand for its eyedrop ...

Research shows that patients with Demodex blepharitis have significantly higher prevalence of ocular bacterial or fungal ...

Patients with Demodex blepharitis show significantly higher rates of microbial co-infestation than healthy controls.

OMAHA, NE - January 22, 2026 - PRESSADVANTAGE - Modern Vision Solutions has announced the publication of a new article, ...

Tarsus Pharmaceuticals (NASDAQ:TARS) reported fourth-quarter and full-year 2025 results highlighting rapid growth for XDEMVY, the company’s FDA-approved treatment for Demodex blepharitis (DB), and ...

Melissa Quinn is a senior reporter for CBSNews.com, where she covers U.S. politics, with a focus on the Supreme Court and federal courts. Overseen by the conservative Heritage Foundation, the ...

A bill touted by President Donald Trump that would require individuals provide proof of citizenship upon registering to vote is making its way through Congress and raising alarm bells among voter ...

Today, the data and real-world experience validate our conviction. In just two years since launch, XDEMVY has fundamentally changed the eye care experience. First, XDEMVY is delivering consistent, ...

A total of 20 athletes are competing under the designation "AIN" at the Milan Cortina Olympics - an abbreviation often clearly visible on their uniforms. The letters have trigged a number of questions ...

Before we begin, I encourage everyone to visit the Investor section of the Tarsus website to view the earnings release and re ...

Marianne Bonner, CPCU, ARM, covers business insurance topics for Investopedia, building on 30 years of experience working in the insurance industry. She has written extensively for The Risk Report, ...